ArticlePrzeglad gastroenterologiczny2026
Oncostatin M as a key predictive factor for anti-TNF-
Article in Przeglad gastroenterologiczny, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Reliable biomarkers are needed to predict response to anti-TNF-α therapy in patients with inflammatory bowel disease. Aim: The primary aim of this study was to evaluate the usefulness of serum oncostatin M (OSM) as a marker of response to anti-TNF-α therapy in patients with inflammatory bowel disease (IBD). A secondary endpoint was the identification of additional factors that may influence the response to anti-TNF-α treatment. Material and methods: The study included 135 patients treated with infliximab or adalimumab. Serum OSM and faecal calprotectin levels were measured at baseline and after 14 weeks of therapy. Results: Baseline OSM levels were significantly lower in responders than in non-responders (MD = -348.07; 95% CI: -400.72 to -242.96; Conclusions: Several factors - including age, disease location, concomitant IBD-associated spondyloarthropathy, calprotectin levels - may influence the response to anti-TNF-α therapy. However, only low serum OSM concentration was consistently associated with a better treatment response and may represent a promising biomarker and potential therapeutic target in IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.